Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Francesca SPERANDI"'
Autor:
Andrea De Giglio, Federico Zacchini, Giulia Venturi, Alessandro Di Federico, Claudia Parisi, Filippo Gustavo Dall’Olio, Ilaria Ricciotti, Valentina Favorito, Ambrogio Gagliano, Dario De Biase, Thais Maloberti, Annalisa Altimari, Elisa Gruppioni, Giovanni Tallini, Barbara Melotti, Francesca Sperandi, Francesco Gelsomino, Lorenzo Montanaro, Andrea Ardizzoni
Publikováno v:
The Journal of Liquid Biopsy, Vol 6, Iss , Pp 100161- (2024)
Background: The frontline management of non-oncogene addicted non-small cell lung cancer (NSCLC) involves immune-checkpoint inhibitors (ICI) alone or combined with chemotherapy (CT-ICI). The dynamic landscape of KRAS-positive NSCLC presents a spectru
Externí odkaz:
https://doaj.org/article/2c56aaec253547179fef60b4afe1ddfb
Autor:
Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti
Publikováno v:
Drugs in Context, Vol 11, Pp 1-12 (2022)
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signall
Externí odkaz:
https://doaj.org/article/810b165b7adb43dc9e5707cb1f20d5dc
BRAF‐mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis
Autor:
Francesca Abbati, Annalisa Altimari, Barbara Corti, Emi Dika, Francesca Sperandi, Barbara Melotti
Publikováno v:
Clinical Case Reports, Vol 9, Iss 4, Pp 2200-2204 (2021)
Abstract We report the case of a young woman who developed metastatic melanoma in the inguinal nodal region, which acquired chondrosarcomatous differentiation and preserved the BRAF mutation found in the primary tumor. The patient was treated with a
Externí odkaz:
https://doaj.org/article/7dcff667c70b43a28436b01a14ecc4ea
Autor:
Maurizio Zompatori, Andrea Ardizzoni, Giuseppe Lamberti, Francesco Gelsomino, Claudia Parisi, Stefania Salvagni, Francesca Sperandi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Non-small cell lung cancer (NSCLC) can be associated with pulmonary cystic airspaces (pCAs). pCAs are radiologically classified into four types based on whether the nodule or mass extrudes the wall of the pCAs. In most cases, response evaluation of t
Externí odkaz:
https://doaj.org/article/7f1174f10cbf43639e4fe4cd3367be7f
Autor:
Giuseppe Lamberti, Francesco Gelsomino, Stefano Brocchi, Antonio Poerio, Barbara Melotti, Francesca Sperandi, Mauro Gargiulo, Claudio Borghi, Michelangelo Fiorentino, Andrea Ardizzoni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Atherosclerosis is considered an irreversible process, with crucial contribution of inflammation and immune cells. Impact of cancer immunotherapy on a partly immune-driven disease, such as atherosclerosis, is poorly understood, but preclinical models
Externí odkaz:
https://doaj.org/article/03939e2192414974837dc64dc799c40e
Autor:
Rossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, Roberta Buosi, Daniele Santini, Agnese Montanino, Carlo Carnaghi, Marcello Tiseo, Rita Chiari, Andrea Camerini, Sandro Barni, Valeria De Marino, Daris Ferrari, Antonella Cristofano, Laura Doni, Federica Freddari, Daniele Fumagalli, Luigi Portalone, Roberta Sarmiento, Giovanni Schinzari, Francesca Sperandi, Marcello Tucci, Alessandro Inno, Libero Ciuffreda, Marita Mariotti, Cinzia Mariani, Miriam Caramanti, Mariangela Torniai, Rosaria Gallucci, Chiara Bennati, Paola Bordi, Lucio Buffoni, Achille Galeassi, Michele Ghidini, Emidio Grossi, Alessandro Morabito, Bruno Vincenzi, Emanuela Arvat
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: Hyponatremia in cancer patients is often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The aim of this observational multicenter study was to analyze the medical and economic implications of SIADH in this
Externí odkaz:
https://doaj.org/article/35962965fe4b448a9213dbbff50072dc
Autor:
Karim Rihawi, Francesco Gelsomino, Francesca Sperandi, Barbara Melotti, Michelangelo Fiorentino, Laura Casolari, Andrea Ardizzoni
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 11 (2017)
Immune checkpoint inhibitors (ICPIs) are considered one of the most important breakthroughs in cancer treatment of the past decade; notably, different studies of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors
Externí odkaz:
https://doaj.org/article/57544b8bd285492284c3503cd8aa0d3b
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0c437e84aaed8cbee905d422ee213da
https://doi.org/10.1016/j.lungcan.2022.10.007
https://doi.org/10.1016/j.lungcan.2022.10.007
Autor:
Alessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni
Publikováno v:
JNCI: Journal of the National Cancer Institute. 115:29-42
Background Many patients with non-small cell lung cancer (NSCLC) derive poor benefit from immunotherapy (IO). For some of them, adding chemotherapy (CT) can improve the outcomes, but the reliability of programmed death–ligand 1 (PD-L1) expression a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a5fe391b6baf6e2bcb59af201089ddb
https://doi.org/10.1093/jnci/djac205
https://doi.org/10.1093/jnci/djac205
Autor:
Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verzè, Cinzia Azzoni, Lorena Bottarelli, Monica Pluchino, Maria Pia Armillotta, Annalisa Ubaldi, Annalisa Altimari, Elisa Gruppioni, Francesca Sperandi, Elisa Andrini, Giorgia Guaitoli, Stefania Bettelli, Lucia Longo, Federica Bertolini, Fausto Barbieri, Maria Pagano, Candida Bonelli, Elena Tagliavini, Davide Nicoli, Alessandro Ubiali, Adriano Zangrandi, Serena Trubini, Manuela Proietto, Letizia Gnetti, Marcello Tiseo
Publikováno v:
Clinical Lung Cancer. 23:e478-e488
Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible for long time, but new drugs have recently demonstrated promising results. Evidence on the outcome of KRAS-mutant advanced-NSCLC treated with new standard regimens are still scarce. Thus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7053999a8fa97bfc0f7fa4b0494b6c82
https://doi.org/10.1016/j.cllc.2022.07.005
https://doi.org/10.1016/j.cllc.2022.07.005